Ken Griffin Y M Abs Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$9.95 - $15.39 $8,955 - $13,851	900 Added 4.64%	20,300 $266,000
Q2 2024 Aug 14, 2024	BUY	$11.6 - $17.25 $102,080 - $151,800	8,800 Added 83.02%	19,400 $234,000
Q1 2024 May 15, 2024	BUY	$6.57 - $18.69 $59,130 - $168,210	9,000 Added 562.5%	10,600 $172,000
Q4 2023 Feb 14, 2024	SELL	$4.88 - $7.42 $6,344 - $9,646	-1,300 Reduced 44.83%	1,600 $10,000
Q3 2023 Nov 14, 2023	SELL	$4.86 - $7.23 $10,692 - $15,906	-2,200 Reduced 43.14%	2,900 $15,000
Q2 2023 Aug 14, 2023	SELL	$5.68 - $10.34 $20,448 - $37,224	-3,600 Reduced 41.38%	5,100 $34,000
Q1 2023 May 15, 2023	BUY	$2.83 - $5.11 $12,169 - $21,973	4,300 Added 97.73%	8,700 $43,000
Q4 2022 Feb 14, 2023	SELL	$3.0 - $15.17 $145,200 - $734,228	-48,400 Reduced 91.67%	4,400 $21,000
Q3 2022 Nov 14, 2022	SELL	$13.96 - $19.67 $523,500 - $737,625	-37,500 Reduced 41.53%	52,800 $761,000

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $487M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.